• 2025
  • 2024
  • 2023
  • 2022
  • 2021

R&D Pipeline

R&D Pipeline (In-House)

As of May 2025

Generic name
/ Development code
Expected indications Category Development stage Development classification

Linzagolix
/ KLH-2109

Uterine fibroids GnRH receptor antagonist NDA Kissei
Endometriosis Phase III
Kissei
Cretostimogene grenadenorepvec
/ CG0070
Non-muscle-invasive bladder cancer Oncolytic Viral Therapy Phase III In-licensed /
CG Oncology (U.S.)
Rovatirelin
/ KPS-0373
Spinocerebellar degeneration TRH receptor agonist Phase III
In-licensed /
Shionogi (Japan)
Matsupexole
/ KDT-3594
Parkinson's disease Dopamine receptor agonist Phase II Kissei




R&D Pipeline (Out-Licensing)

As of May 2025

Generic name Expected indications Category Countries & Regions Development company Development stage
Linzagolix Uterine fibroids GnRH receptor antagonist 4 countries* Theramex (U.K.) NDA
Taiwan Synmosa Biopharma (Taiwan) NDA
Endometriosis EU Theramex (U.K.) Approved
Fostamatinib Chronic idiopathic thrombocytopenic purpura Tyrosine kinase inhibitor Korea JW Pharmaceutical (Korea) Launch preparation
Silodosin Dysuria associated with benign prostatic hyperplasia Alpha 1A adrenergic receptor antagonist Vietnam, etc. Eisai (Japan) NDA

* Switzerland, Brazil, Isreal and Republic of South Africa